NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

VRC 326 (001614): A Phase I Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institute of Allergy and Infectious Diseases (NIAID)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 50 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women;
Adults who are or may become unable to consent;


Seasonal Influenza;
Experimental Vaccine;
Immune Response;
Universal Influenza Vaccine;
Respiratory Illness;
Healthy Adults

Recruitment Keyword(s)




Investigational Drug(s)

VRC-FLUMOS0116-00-VP (FluMos-v2)

Investigational Device(s)



Biological/Vaccine: VRC-FLUMOS0116-00-VP( FLUMos-v2)

Supporting Site

National Institute of Allergy and Infectious Diseases


Influenza (flu) virus causes 3 to 5 million cases of severe illness and up to 650,000 deaths per year worldwide. Current vaccines work well against single strains of flu virus. But no single vaccine works well against all flu viruses that can cause illness.


To test an experimental flu vaccine (FluMos-v2) in healthy adults.


Healthy adults aged 18 to 50 years.


Participants will have 11 clinic visits in 10 months. They must agree not to get a licensed flu vaccine while taking part in this study.

FluMos-v2 will be given with a needle injected into a muscle in the upper arm. Participants will receive a follow-up phone call the following day.

Participants will be given a diary card, a ruler, and a thermometer. They will take their temperature every day for 7 days after receiving the shot. They will measure any skin changes at the injection site. They will record their findings and how they feel.

Participants will receive a second FluMos-v2 shot after 4 months. They will repeat the other follow-up steps.

Participants will have 9 other clinic follow-up visits. Blood will be drawn at each visit.

Participants should also come to the clinic if they develop flu-like symptoms during the study.

Participants may opt for an apheresis 2 weeks after each shot: Blood will be removed through a needle in the vein of 1 arm. The blood will run through a machine that separates out the white blood cells. The remaining blood is returned through a needle in the other arm.

--Back to Top--



A subject must meet all of the following criteria:

-Healthy adults between the ages of 18-50 years, inclusive

-Based on history and physical examination, in good general health and without history of any of the conditions listed in the exclusion criteria

-For Part A: Received at least one licensed influenza vaccine from 2018 through the 2022-2023 influenza season

-Able and willing to complete the informed consent process

-For Part A: Available for clinic visits for 40 weeks after enrollment, including through the 2023-2024 influenza season

-For Part B: Available for clinic visits for 40 weeks after enrollment, including through the 2024-2025 influenza season

-For Part B: Agrees to undergo four lymph node FNAs.

-Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process

-Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) <= 35 within the 56 days before enrollment

-For both Parts A and B: Agrees to not receive the 2023-2024 licensed influenza vaccination during study participation due to potential confounding of study results

-Willing to have blood samples collected, stored indefinitely, and used for research purposes

-For Part B: WIlling to have lymph node samples collected, stored indefinitely, and used for research puposes

Laboratory Criteria within 56 days before enrollment

-White blood cells (WBC) and differential within institutional normal range or accompanied by the site Principal Investigator (PI) or designee approval

-Total lymphocyte count >= 800 cells/microliter

-Platelets = 125,000 - 500,000 cells/microliter

-Hemoglobin within institutional normal range or accompanied by the PI or designee approval

-Alanine aminotransferase (ALT) <= 1.25 x institutional upper limit of normal (ULN)

-Aspartate aminotransferase (AST) <= 1.25 x institutional ULN

-Alkaline phosphatase (ALP) <1.1 x institutional ULN

-Total bilirubin within institutional normal range or accompanied by the PI or designee approval

-Serum creatinine <= 1.1 x institutional ULN

-Negative for HIV infection by an FDA-approved method of detection

Criteria applicable to women of childbearing potential:

-Negative beta-human chorionic gonadotropin (Beta-HCG) pregnancy test (urine or serum) on the day of enrollment

-Agrees to use an effective means of birth control from at least 21 days prior to enrollment through the end of the study for sample collection.


A subject will be excluded if one or more of the following conditions apply:

-Breast-feeding or planning to become pregnant during the study

Subject has received any of the following substances:

-More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment

-Blood products within 16 weeks prior to enrollment

-Live attenuated vaccines within 4 weeks prior to enrollment

-Inactivated vaccines within 2 weeks prior to enrollment

-Investigational research agents within 4 weeks prior to enrollment or planning to receive investigational products while on the study (Note: SARS-CoV-2 vaccines licensed and/or approved by emergency use authorization are not exclusionary, but are subject to the criteria for timing of inactivated vaccines or mRNA vaccines)

-mRNA vaccines within 4 weeks prior to enrollment

-Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule

-Current anti-TB prophylaxis or therapy

-Receipt of investigational ferritin-based nanoparticle influenza vaccines, with the exception of participants previously enrolled in the VRC 316 study as follows: Group 2 (HA-F A/Sing prime, HA-F A/Sing boost), 3A (DNA A/Sing prime, HA-F A/Sing boost) or 4A (HA-F A/Sing prime, HA-F A/Sing boost).

-Receipt of the mosaic quadrivalent influenza vaccine VRC-FLUMOS0111-00-VP (FluMos-v1)

-Receipt of any licensed influenza vaccine within 6 months prior to enrollment.

-For Part A and Part B:Receipt of the 2023-2024 licensed influenza vaccine

-For Part B: Plan to or are required to receive the 2024-2025 licensed influenza vaccine

-For Part B: Receipt of any licensed seasonal influenza vaccine since the 2020-2021 influenza season; including the 2021-2022 influenza season through the 2024-2025 influenza season.

Subject has a history of any of the following clinically significant conditions:

-Serious reactions to vaccines that preclude receipt of the study vaccinations as determined by the investigator

-Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema

-Asthma that is not well controlled

-Diabetes mellitus (type I or II), with the exception of gestational diabetes

-Thyroid disease that is not well controlled

-Idiopathic urticaria within the past year

-Autoimmune disease or immunodeficiency

-Hypertension that is not well controlled

-Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws

-Malignancy that is active or history of malignancy that is likely to recur during the period of the study

-Seizure disorder other than 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years

-Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen

-Guillain-Barre Syndrome

-Any medical, psychiatric, or social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject s ability to give informed consent, including but not limited to clinically significant forms of infectious diseases, drug or alcohol abuse, autoimmune diseases, psychiatric disorders, or heart disease.

--Back to Top--


Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JR, Rao SS, Kong WP, Wang L, Nabel GJ. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 2013 Jul 4;499(7456):102-6. doi: 10.1038/nature12202. Epub 2013 May 22. PMID: 23698367; PMCID: PMC8312026.

Corbett KS, Moin SM, Yassine HM, Cagigi A, Kanekiyo M, Boyoglu-Barnum S, Myers SI, Tsybovsky Y, Wheatley AK, Schramm CA, Gillespie RA, Shi W, Wang L, Zhang Y, Andrews SF, Joyce MG, Crank MC, Douek DC, McDermott AB, Mascola JR, Graham BS, Boyington JC. Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. mBio. 2019 Feb 26;10(1):e02810-18. doi: 10.1128/mBio.02810-18. PMID: 30808695; PMCID: PMC6391921.

Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, Gallagher JR, Wang L, Zhang Y, Joyce MG, Lingwood D, Moin SM, Andersen H, Okuno Y, Rao SS, Harris AK, Kwong PD, Mascola JR, Nabel GJ, Graham BS. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med. 2015 Sep;21(9):1065-70. doi: 10.1038/nm.3927. Epub 2015 Aug 24. PMID: 26301691.

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Maxwell R. Norris, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)

VRC Recruitment
National Institute of Allergy and Infectious Diseases (NIAID)

(866) 833-5433

VRC Clinic
National Institute of Allergy and Infectious Diseases (NIAID)
Vaccine Research Center
National Institutes of Health (NIH)
Bethesda, MD 20892

(301) 451-8715

Clinical Trials Number:


--Back to Top--